Skip to product information
Request a Quote
Creatine Monohydrate Powder – High Purity | 1-Day Dispatch Australia | BA-1023
$25.00 AUD
Energy Metabolism · Phosphocreatine System · Biochemical Grade
Creatine Monohydrate
C₄H₉N₃O₂ · H₂O · CAS 6020-87-7 · MW 149.15 g/mol · Anhydrous CAS 57-00-1
Biochemical Grade Purity >98%![]()
Karl Fischer Tested DCD <10 ppm Batch Traceable COA Included
AuSaMicS
Life Science™
Cat No.
BA-1023
CAS No.
6020-87-7
Mol. Weight
149.15 g/mol
Purity
>98%
Storage
15–25°C, dry
Overview
Creatine Monohydrate is the water-containing crystalline form of creatine (N-methylguanidinoacetic acid), a naturally occurring nitrogenous compound synthesised in the liver and kidneys from arginine and glycine. Creatine is predominantly found in skeletal muscle, where it plays a central role in energy metabolism through the phosphocreatine (PCr) system — serving as a rapid phosphate donor for ATP regeneration via creatine kinase.
The monohydrate form contains one molecule of water of crystallisation (~12% w/w), conferring greater stability compared to anhydrous creatine. In solution, creatine exists in equilibrium with its catabolite creatinine; alkaline conditions favour this conversion while acid solutions produce predominantly creatinine. AuSaMicS supplies Creatine Monohydrate at biochemical grade (>98%) with dicyandiamide (DCD) testing, Karl Fischer water content determination, and full COA.
Chemical Identity
| Product Name | Creatine Monohydrate |
| IUPAC Name | 2-(carbamimidoyl-methyl-amino)acetic acid monohydrate |
| Synonyms | Creatine hydrate; N-Methylguanidinoacetic acid monohydrate; Methylguanidoacetic acid monohydrate |
| Catalog No. | BA-1023 |
| CAS No. (Monohydrate) | 6020-87-7 |
| CAS No. (Anhydrous) | 57-00-1 |
| Molecular Formula | C₄H₉N₃O₂ · H₂O |
| Molecular Weight (Monohydrate) | 149.15 g/mol |
| Molecular Weight (Anhydrous) | 131.14 g/mol |
| Appearance | White to off-white crystalline powder |
| Grade | Biochemical Grade (>98%) |
| Packaging | 250 g · 1 kg · 2 kg |
Mechanism & Biochemistry
PCr Energy System
Phosphocreatine + ADP + H+ → Creatine + ATP via creatine kinase — the primary rapid energy buffer in muscle and brain.
Biosynthesis
Synthesised in liver/kidneys: transamidination (arginine + glycine → guanidinoacetate), then methylation by SAM → creatine.
Solution Equilibrium
In aqueous/alkaline solutions: creatine ⇔ creatinine. Acid solutions produce predominantly creatinine. Prepare solutions fresh.
ATP Regeneration
Used with phosphocreatine + creatine kinase in cell-free translation systems as an ATP regenerating system.
CK Assay Substrate
Standard substrate for creatine kinase (CK-MM, CK-MB, CK-BB) isoenzyme activity assays in clinical and research settings.
Neuroprotection
Crosses the blood-brain barrier via SLC6A8 transporter. Studied in Parkinson's, Huntington's, and ALS research.
Applications
| Application | Context | Notes |
|---|---|---|
| Biochemical Research | CK assay substrate; PCr metabolism studies; ATP regenerating systems | Standard substrate for creatine kinase assays |
| Cell-Free Systems | ATP regeneration in in vitro transcription/translation with phosphocreatine + CK | Standard: 8 mM creatine + 20 mM phosphocreatine + CK |
| Cell Culture Supplement | Exogenous energy substrate for cardiomyocytes, neurons, myotubes | Typical: 1–10 mM in culture medium |
| Sports Nutrition | Most studied ergogenic supplement; increases muscle PCr stores; enhances high-intensity exercise performance | Generally regarded as safe (GRAS) |
| Neuroprotection Research | Studies on creatine in neurodegenerative conditions (PD, HD, ALS) | Research and clinical trial applications |
| Analytical Reference | HPLC/NMR/MS reference standard; creatine quantification in biological fluids and food | High purity ensures accurate quantification |
Storage & Packaging
| Storage | 15–25°C, dry, well-ventilated; tightly closed; away from oxidising agents |
| Solution Stability | Prepare fresh — converts to creatinine over time especially at alkaline pH or elevated temperature. Store solutions at 4°C, pH 6–7, ≤7 days. |
| Shelf Life | 3 years from manufacture under correct conditions (see retest date on label) |
| Pack Sizes | 250 g · 1 kg · 2 kg |
AuSaMicS Pty Ltd (ABN 56 676 640 467) · 31 Longview CT, Thomastown VIC 3074, Australia · support@ausamics.com · +61 412 520 598 · www.ausamics.com.au
Product Identification
| Product Name | Creatine Monohydrate |
| Cat No. | BA-1023 |
| CAS (Monohydrate) | 6020-87-7 |
| CAS (Anhydrous) | 57-00-1 |
| MW (Monohydrate) | 149.15 g/mol |
| MW (Anhydrous) | 131.14 g/mol |
| Grade | Biochemical Grade |
| Purity | >98% (anhydrous basis) |
Physical Properties
| Appearance | White to off-white crystalline powder |
| Water Content | ~12.1% w/w (KF spec: 11.5–13.5%) |
| Solubility | ~13.3 mg/mL (1:75) at 20°C; Kb = 9.6×10&sup-;¹² |
| Melting/Decomp. | ~300°C dec.; decomp. 303°C |
| pH (1% solution) | 6.5–8.0 |
| Flash Point | Not applicable |
| Storage | 15–25°C, dry, sealed |
Quality Control Specifications
| Parameter | Specification | Method |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual inspection |
| Purity (HPLC) | >98.0% (anhydrous basis) | HPLC reversed phase, UV 210 nm |
| Identity (IR) | Conforms to Creatine Monohydrate reference spectrum | IR spectroscopy (KBr disc) |
| Identity (LC-MS) | [M+H]+ = 132 consistent with anhydrous MW 131.14 | LC-MS |
| Water Content (KF) | 11.5–13.5% w/w | Karl Fischer titration (Ph. Eur.) |
| Loss on Drying | ≤ 14.0% w/w | 105°C / 2 h (gravimetric) |
| Creatinine (impurity) | ≤ 1.0% w/w | HPLC |
| Dicyandiamide (DCD) | ≤ 10 ppm | HPLC (industrial contaminant) |
| Heavy Metals (Pb equiv.) | ≤ 20 ppm | ICP-MS |
| Arsenic (As) | ≤ 1 ppm | ICP-MS |
| pH (1% solution) | 6.5–8.0 | Potentiometry (ISO 10523) |
Preparation Guidelines
| Aqueous Solution | Dissolve in warm purified water (40–50°C); max practical concentration ~50 mg/mL. Stir or sonicate until clear. |
| Cell Culture | Working concentration: 1–10 mM. Prepare in sterile water; filter-sterilise (0.22 µm); store at 4°C; use within 2 weeks. |
| ATP Regenerating System | 8 mM creatine + 20 mM phosphocreatine + 0.02 mg/mL creatine kinase in cell-free translation buffer. |
| CK Assay | 100 mM stock in 50 mM HEPES pH 7.4; use at 20–50 mM in kinetic CK assay. |
| Solution Stability | pH 6–7 preferred. Alkaline solutions → rapid creatinine formation. Use fresh or store at 4°C ≤7 days. |
| Do NOT Autoclave | Converts to creatinine under autoclave conditions. Use filter sterilisation (0.22 µm) for sterile applications. |
DCD Contamination: Industrial creatine synthesis produces dicyandiamide (DCD) as a by-product. AuSaMicS tests all lots with a specification of ≤10 ppm. Result for Lot CRE260301: <2 ppm.
AuSaMicS Pty Ltd (ABN 56 676 640 467) · 31 Longview CT, Thomastown VIC 3074, Australia · support@ausamics.com · www.ausamics.com.au
Safety Data Sheet — GHS Format (Australian WHS Hazardous Chemicals Regulations 2023)
HAZARDOUS CHEMICAL. NON-DANGEROUS GOODS. Issue Date: March 2026 · Rev: 1.0
Based on: CCC Ingredients Pty Ltd SDS Chemwatch 17430-1 Version 6.1 (20/06/2022)
HAZARDOUS CHEMICAL. NON-DANGEROUS GOODS. Issue Date: March 2026 · Rev: 1.0
Based on: CCC Ingredients Pty Ltd SDS Chemwatch 17430-1 Version 6.1 (20/06/2022)
Section 1 — Identification
| Product Name | Creatine Monohydrate — BA-1023 |
| CAS No. (Monohydrate) | 6020-87-7 |
| CAS No. (Anhydrous) | 57-00-1 |
| Intended Use | Biochemical reagent, energy metabolism research, cell culture supplement, ATP regenerating systems, sports nutrition |
| Supplier | AuSaMicS Pty Ltd, 31 Longview CT, Thomastown VIC 3074, Australia |
| ABN | 56 676 640 467 |
| Phone / Emergency | +61 412 520 598 · Poisons Information Centre: 13 11 26 (24h) |
| Email / Web | support@ausamics.com · www.ausamics.com.au |
| Poisons Schedule | Not Applicable |
Section 2 — Hazard Identification
⚠ WARNING — H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation.
Note: Creatine Monohydrate is NOT classified as a skin sensitiser (H317 does NOT apply — contrast with Taurine BA-1022).
Note: Creatine Monohydrate is NOT classified as a skin sensitiser (H317 does NOT apply — contrast with Taurine BA-1022).
| GHS Classification | Skin Corrosion/Irritation Cat. 2 (H315) · Serious Eye Damage/Irritation Cat. 2A (H319) · STOT Single Exposure Cat. 3 (H335) |
| Signal Word | WARNING |
| GHS Pictogram | GHS07 (Exclamation mark) |
| Prevention | P261 · P264 · P271 · P280 |
| Response | P302+P352 · P304+P340 · P305+P351+P338 · P312 · P332+P313 · P337+P313 · P362+P364 |
| Storage | P403+P233 · P405 |
| Disposal | P501 |
Section 3 — Composition
| CAS No. | % Weight | Name | GHS Classification |
|---|---|---|---|
| 6020-87-7 / 57-00-1 | >98% | Creatine Monohydrate / Creatine (C₄H₉N₃O₂·H₂O) | H315 · H319 · H335 |
| 60-27-5 | trace | Creatinine (solution equilibrium product) | Contact allergen (see Sec.11) |
| — | <2% | Moisture and trace impurities | Not classified |
Sections 4–8 — First Aid, Fire, Spill, Handling, PPE
| Eye Contact | Wash immediately with fresh running water ≥15 min. Keep eyelids apart. Seek medical attention without delay if pain persists. Contact lens removal: skilled personnel only. |
| Skin Contact | Remove contaminated clothing immediately. Flush with running water and soap. Seek medical attention if irritation develops. |
| Inhalation | Remove to fresh air. Keep warm and rested. Artificial respiration if not breathing. Transport to hospital without delay. |
| Ingestion | Give glass of water. First aid generally not required (LD50 rat oral/dermal >2000 mg/kg). Contact Poisons Centre (13 11 26) if in doubt. |
| Fire | Foam; dry chemical; BCF; CO₂. SCBA + protective gloves. Combustion products: CO, CO₂, NOₓ. |
| Spill | Wear P2 respirator, gloves, goggles. Use HEPA vacuum or damp cloth. Avoid generating dust. DO NOT discharge to drains or waterways. |
| Handling | Use in well-ventilated area. Minimise dust. Keep away from heat/sparks/flame. Organic powder — eliminate ignition sources. |
| Storage | 15–25°C, dry, tightly closed. Away from oxidising agents and foodstuffs. PE or PP containers. |
| Respiratory PPE | P2 dust filter (AS/NZS 1716) for powder handling |
| Eye/Face Protection | Safety glasses with side shields (AS/NZS 1337.1); goggles if splash risk |
| Hand Protection | Nitrile rubber, polychloroprene, or butyl rubber gloves (AS/NZS 2161) |
| Body Protection | Lab coat or overalls; PVC apron for bulk handling |
Sections 9–16 — Properties, Stability, Toxicology, Ecology, Disposal, Transport, Regulatory
| Physical State | White to off-white crystalline powder (divided solid) |
| Solubility | Partly miscible — ~13.3 mg/mL (1:75) at 20°C; Kb = 9.6×10&sup-;¹² |
| Melting/Decomposition | ~300°C dec.; decomposition temperature 303°C |
| Solution Note | Alkaline/aqueous solutions: equilibrium with creatinine. Acid solutions: predominantly creatinine. |
| Acute Oral Toxicity | LOW — LD50 (rat, oral): >2000 mg/kg. NOT classified. |
| Acute Dermal Toxicity | LOW — LD50 (rat, dermal): >2000 mg/kg. NOT classified. |
| Skin Irritation | H315 — Causes skin irritation (Cat. 2) |
| Eye Irritation | H319 — Causes serious eye irritation (Cat. 2A) |
| Skin Sensitisation | NOT CLASSIFIED (H317 does not apply to Creatine) |
| Respiratory | H335 — May cause respiratory irritation; RADS possible in sensitised individuals |
| Carcinogenicity | Not classified; not listed by IARC or NTP |
| DCD Contamination | Industrial synthesis by-product; tested in all lots; specification ≤10 ppm |
| Aquatic Toxicity (Algae) | EC50 (algae, 72h): >100 mg/L |
| Aquatic Toxicity (Fish) | LC50 (fish, 96h): >84.6 mg/L; NOEC ≥84.6 mg/L |
| Aquatic Toxicity (Crustacea) | EC50 (crustacea, 48h): >880 mg/L |
| Persistence | LOW in water/soil and air (biodegrades) |
| Bioaccumulation | LOW — LogKOW = -3.7217 (creatine) |
| Disposal | Landfill (licensed chemical waste) or incineration. DO NOT discharge to sewer or waterways. |
| Transport | NOT REGULATED — ADG / IATA / IMDG. Marine Pollutant: No. HAZCHEM: N/A. |
| AIIC (Australia) | Listed — CAS 57-00-1 (creatine); CAS 6020-87-7 (monohydrate); CAS 60-27-5 (creatinine) |
| WHS Regulations | Classified hazardous chemical under WHS (Hazardous Chemicals) Regulations 2023 — H315, H319, H335 |
| Ph. Eur. / BP | Creatine Monohydrate monograph available |
AuSaMicS Pty Ltd (ABN 56 676 640 467) · 31 Longview CT, Thomastown VIC 3074, Australia · support@ausamics.com · +61 412 520 598 · www.ausamics.com.au
Based on CCC Ingredients Pty Ltd SDS Chemwatch 17430-1 Version 6.1 (20/06/2022) and ECHA registered substances data.
Based on CCC Ingredients Pty Ltd SDS Chemwatch 17430-1 Version 6.1 (20/06/2022) and ECHA registered substances data.
Product Details
| Product Name | Creatine Monohydrate |
| Catalog No. | BA-1023 |
| CAS No. (Monohydrate) | 6020-87-7 |
| CAS No. (Anhydrous) | 57-00-1 |
| Molecular Formula | C₄H₉N₃O₂ · H₂O |
| Lot No. | CRE260301 |
| Mfg. Date | March 2026 |
| Retest Date | March 2029 |
| Grade | Biochemical Grade (>98%) |
Document Information
| COA No. | COA-BA-1023-L001 |
| Issue Date | March 2026 |
| Issued By | AuSaMicS Quality Control |
| Test Reference | In-house / Ph. Eur. / BP |
Test Results & Analytical Data
| Test Parameter | Specification | Method | Result | Status |
|---|---|---|---|---|
| Appearance | White to off-white crystalline powder | Visual inspection | Conforms | PASS |
| Identity (IR) | Conforms to Creatine Monohydrate reference spectrum | IR spectroscopy (KBr disc) | Conforms | PASS |
| Identity (LC-MS) | [M+H]+ = 132 (anhydrous MW 131.14) | LC-MS | Confirmed | PASS |
| Purity (HPLC) | >98.0% (anhydrous basis) | HPLC reversed phase, UV 210 nm | 98.9% | PASS |
| Water Content (KF) | 11.5–13.5% w/w | Karl Fischer titration (Ph. Eur.) | 12.2% | PASS |
| Loss on Drying | ≤ 14.0% w/w | 105°C / 2 h (gravimetric) | 12.4% | PASS |
| Creatinine (impurity) | ≤ 1.0% w/w | HPLC | 0.31% | PASS |
| Dicyandiamide (DCD) | ≤ 10 ppm | HPLC | <2 ppm | PASS |
| pH (1% aqueous solution) | 6.5–8.0 | Potentiometry (ISO 10523) | 7.1 | PASS |
| Heavy Metals (Pb equiv.) | ≤ 20 ppm | ICP-MS | <5 ppm | PASS |
| Arsenic (As) | ≤ 1 ppm | ICP-MS | <0.2 ppm | PASS |
| CAS Identity Verification | CAS 6020-87-7 / 57-00-1 confirmed | LC-MS vs. reference standard | Confirmed | CONFORM |
Conclusion: Lot CRE260301 fully meets all release specifications for Creatine Monohydrate (CAS 6020-87-7). Purity 98.9% (>98% spec.), water content 12.2% (spec. 11.5–13.5%), creatinine 0.31% (≤1.0% spec.), DCD <2 ppm (≤10 ppm spec.). All heavy metals within limits. This lot is RELEASED for use.
Quality Control Analyst
AuSaMicS Quality Control Department
Date: March 2026 | Signature: _______________
Hassan Salimi
Founder & Technical Director, AuSaMicS Pty Ltd
Date: March 2026 | Signature: _______________
AuSaMicS Pty Ltd (ABN 56 676 640 467) warrants this product meets specifications at time of manufacture. Results specific to Lot CRE260301 only. · 31 Longview CT, Thomastown VIC 3074, Australia · support@ausamics.com · +61 412 520 598 · www.ausamics.com.au
AuSaMicS Pty Ltd · ABN 56 676 640 467 · 31 Longview CT, Thomastown VIC 3074, Australia · support@ausamics.com · +61 412 520 598 · www.ausamics.com.au